user
menu
letter
Sign InRegister
langEnglisharrow

Human LILRA4 / CD85g / ILT7 Protein, His Tag

製品番号/仕様
価格
Availability
数量
LI4-H52H5-100ug
$360.00
In Stock - Delivery in 1-2 business days
LI4-H52H5-1mg (500ug X 2)
$2,615.00
In Stock - Delivery in 2 weeks
LI4-H52H5
製品金額 :
$ 0
推奨新製品 Request Quote
Contact Us
Contact Us
製品金額:
$ 0
Request Quote
製品詳細
データ表示
Reviews & Citations
Resources
  • 製品詳細
  • データ表示
  • Reviews & Citations
  • Important Statement
  • Resources
Synonyms

LILRA4, CD85g, ILT7, ILT-7

Source

Human LILRA4 Protein, His Tag (LI4-H52H5) is expressed from human 293 cells (HEK293). It contains AA Glu 24 - Asn 446 (Accession # P59901-1).

Predicted N-terminus: Glu 24

Molecular Characterization
Other Tags and Version Biotin & Other Labeled Version

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 48.5 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Purity

>90% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Shipping and Storage

This product is shipped at ambient temperature.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System

バックグランド

Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4/ILT7/CD85g) is a marker of plasmacytoid dendritic cells (pDCs), which are reported to be a major source of the abnormally high levels of IFNα associated with autoimmune diseases. Targeting LILRA4 with therapeutic antibodies to promote killing of these IFNα-producing pDCs is being investigated as a novel approach to alleviating the symptoms of autoimmune diseases. LILRA4 is an immunoglobulin-like protein preferentially expressed on the surface of human plasmacytoid dendritic cells (pDCs). It interacts with bone marrow stromal cell antigen 2 to control the Toll-like receptor (TLR) driven response by pDCs to viral infection. It may also be involved in modulating pDC-tumour interactions. pDCs are a source of the excess IFNα which drives autoimmune disease symptoms.